Peginterferon alfa-2a
- Generic Name
- Peginterferon alfa-2a
- Brand Names
- Pegasys
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 198153-51-4
- Unique Ingredient Identifier
- Q46947FE7K
- Background
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, HBeAg Positive Chronic Hepatitis B
- Associated Therapies
- -
Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
- First Posted Date
- 2003-03-25
- Last Posted Date
- 2013-12-06
- Target Recruit Count
- 58
- Registration Number
- NCT00056862
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Treatment of Hepatitis C in Hemophilic Patients With HIV
- Conditions
- First Posted Date
- 2003-02-27
- Last Posted Date
- 2008-07-30
- Target Recruit Count
- 22
- Registration Number
- NCT00055341
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin
- Conditions
- First Posted Date
- 2002-06-19
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- SciClone Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT00039962
- Locations
- 🇺🇸
Digestive Healthcare of Georgia, Atlanta, Georgia, United States
🇺🇸Scripps Clinic, La Jolla, California, United States
🇺🇸Huntington Memorial Hospital, Pasadena, California, United States
Hepatitis C Antiviral Resistance in African-Americans
- First Posted Date
- 2002-06-10
- Last Posted Date
- 2017-08-03
- Target Recruit Count
- 401
- Registration Number
- NCT00038974
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2001-12-12
- Last Posted Date
- 2013-11-08
- Target Recruit Count
- 50
- Registration Number
- NCT00028093
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 132
- Registration Number
- NCT00008463
- Locations
- 🇺🇸
Ucsf Aids Crs, San Francisco, California, United States
🇺🇸The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
- Conditions
- Interventions
- First Posted Date
- 2000-08-09
- Last Posted Date
- 2020-05-12
- Target Recruit Count
- 1050
- Registration Number
- NCT00006164
- Locations
- 🇺🇸
USC School of Medicine, Los Angeles, California, United States
🇺🇸University of Connecticut Health Center, Farmington, Connecticut, United States
🇺🇸University of Texas Southwestern - Dallas, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.